Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma?
Hepatobiliary Surg Nutr
.
2022 Dec;11(6):927-930.
doi: 10.21037/hbsn-22-510.
Authors
Takeshi Hatanaka
1
,
Atsushi Naganuma
2
,
Yutaka Yata
3
,
Satoru Kakizaki
4
Affiliations
1
Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
2
Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
3
Department of Gastroenterology, Hanwa Memorial Hospital, Osaka, Japan.
4
Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
PMID:
36523927
PMCID:
PMC9745629
DOI:
10.21037/hbsn-22-510
No abstract available
Publication types
Editorial